
Pfizer adds a new acquisition. The American laboratory has reached a definitive agreement by which will acquire for 5,400 million dollars (5,303 million euros) Global Blood Therapeutics (GBT)as reported by the company in a statement.
It is a biopharmaceutical company dedicated to the discovery and development of treatments such as sickle cell disease (SCD). Under the terms of the transaction, which was unanimously approved by the boards of directors of the two companies, Pfizer will acquire all outstanding shares of GBT at a unit price of $68.5.
“Sickle cell disease is the most common inherited blood disorder and disproportionately affects people of African descent,” said Albert Bourla, Pfizer Chairman and CEO.
Pfizer plans to finance the purchase of GBT with available cash
The American giant plans to finance the acquisition of GBT with the available cash. However, the transaction is subject to customary closing conditions, including receipt of regulatory approvals and GBT shareholder approval.
The pharmaceutical company has obtained 17,769 million dollars of net profit in the first half of 2022, which represents an increase of 70% compared to the same period of 2021. In addition, the company’s sales until June have grown by 60%, reaching 53,402 million dollars.
In the second quarter, Pfizer has also recorded a net attributable profit of 9,906 million dollars, which represents an increase of 78% compared to the same quarter of the previous year.